de Vries ST, Denig P, Lasheras Ruiz C, Houÿez F, Wong L, Sutcliffe A, Mol PGM; IMI Web-RADR Work Package 3b Consortium
Drug Saf. doi: 10.1007/s40264-018-0648-0
2018-03-02
https://www.ncbi.nlm.nih.gov/pubmed/29500800
Previously, an app has been developed for healthcare professionals (HCPs) and patients to report adverse drug reactions (ADRs) to national medicines agencies and to receive drug safety information. This study aimed to assess (1) European HCPs’ and patients’ interest in an app for this two-way risk communication; (2) their preferences and perceptions towards specific app characteristics; and (3) which HCPs and patients are particularly interested in the app. In addition, these aspects were studied specifically for the countries where such an app was already available, i.e. Croatia, The Netherlands, and The UK.